T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies.Dublin, Sept. 24, 2026 (GLOBE ...
For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving. It’s important for patients receiving bispecific antibodies for lymphoma or ...
Poolbeg Pharma plc announced that a South Korean patent relating to POLB 001 has been formally granted. The patent, entitled "Medicinal products and methods for the alleviation of cancer immunotherapy ...
CytoAgents – a clinical-stage biotechnology company dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS) – announced that it has been awarded a $2 million ...
A significant concern with CRS in drug development is its unpredictability, both in terms of when and how severely it will manifest in humans. Traditional preclinical models, such as non-human ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents, Inc., a clinical-stage biotechnology company developing a safe, effective treatment for Cytokine Release Syndrome (CRS), today announced that it has initiated ...
Immune-evading CAR-NK cells maintained a population in mice long enough to eliminate cancer whilst avoiding cytokine release syndrome. Massachusetts Institute of Technology (MIT) and Harvard Medical ...
PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc. (the Company), a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), ...
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
Unmet Social Needs Among Cancer Survivors Who Were Concomitant Caregivers: A Cross-Sectional Analysis of the Health Information National Trends Survey Talquetamab is a G protein–coupled receptor class ...
Discover effective strategies for monitoring and managing CRS toxicity and ICANS, enhancing patient care and reducing burdens in treatment. Bispecific antibodies have transformed the treatment ...
Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results